Molecular mechanisms of l-DOPA-induced dyskinesia.
International Review of Neurobiology. 2011-01-01; : 95-122
DOI: 10.1016/b978-0-12-381328-2.00004-3
Read on PubMed
1. Int Rev Neurobiol. 2011;98:95-122. doi: 10.1016/B978-0-12-381328-2.00004-3.
Molecular mechanisms of l-DOPA-induced dyskinesia.
Fisone G(1), Bezard E.
Author information:
(1)Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
Parkinson’s disease (PD), a common neurodegenerative disorder caused by the loss
of the dopaminergic input to the basal ganglia, is commonly treated with l-DOPA.
Use of this drug, however, is severely limited by the development of dystonic and
choreic motor complications, or dyskinesia. This chapter describes the molecular
mechanisms implicated in the emergence and manifestation of l-DOPA-induced
dyskinesia (LID). Particular emphasis is given to the role played in this
condition by abnormalities in signal transduction at the level of the medium
spiny neurons (MSNs) of the striatum, which are the principal target of l-DOPA.
Recent evidence pointing to pre-synaptic dysregulation is also discussed.
Copyright © 2011 Elsevier Inc. All rights reserved.
DOI: 10.1016/B978-0-12-381328-2.00004-3
PMID: 21907084 [Indexed for MEDLINE]